Minimization of calcineurin inhibitors: A review of de-novo strategies and conversion algorithms

Current Opinion in Organ Transplantation

Volumn 12, Issue 6, 2007, Pages 624-635

  Kahan, Barry D ^a   Etheridge, Whitson B ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Calcineurin inhibitors; Mycophenolic acid analogs; Nephrotoxicity; Sirolimus

Indexed keywords

4 [N [1 (2 CYANO 1 OXOETHYL) 4 METHYL 3 PIPERIDINYL] N METHYLAMINO]PYRROLO[2,3 D]PYRIMIDINE; ALEMTUZUMAB; AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; CYCLOSPORIN A; DACLIZUMAB; EVEROLIMUS; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS;

ACUTE GRAFT REJECTION; ADJUVANT THERAPY; ALLOIMMUNITY; ANEMIA; ANTIBODY PRODUCTION; AREA UNDER THE CURVE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG INHIBITION; DRUG MECHANISM; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GLOMERULUS FILTRATION RATE; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LYMPHOCYTE ACTIVATION; META ANALYSIS; NEPHROTOXICITY; NONHUMAN; ORGAN TRANSPLANTATION; PRESCRIPTION; PROTEINURIA; REVIEW; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT;

EID: 36249027476     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e3282f1fbec     Document Type: Review

References (112)

1. Kahan BD. Cyclosporine. N Engl J Med 1989; 321:1725-1738.
2. Lanese DM, Falk SA, Conger JD. Sequential agonist activation and site-specific mediation of acute cyclosporine constriction in rat renal arterioles. Transplantation 1994; 58:1371-1378.
3. Castello L, Sainaghi PP, Bergamasco L, et al. Pathways of glomerular toxicity of cyclosporine-A: An "in vitro" study. J Physiol Pharmacol 2005; 56:649-660.
4. Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation on nonrenal organ. N Engl J Med 2003; 349:931-940.
5. Shihab FS, Bennett WM, Tanner AM, et al. Mechanism of fibrosis in experimental tacrolimus nephrotoxicity. Transplantation 1997; 64:1829-1837.
6. Thomas SE, Andoh TF, Pichler RH, et al. Accelerated apoptosis characterizes cyclosporine-associated interstitial fibrosis. Kidney Int 1998; 53:897-908.
7. Nankivell BJ, Borrows RJ, Fung CL, et al. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349:2326-2333.
8. Palmer BF, Toto RD. Severe neurologic toxicity induced by cyclosporine A in three renal transplant patients. Am J Kidney Dis 1991; 18:116-121.
9. Chrysostomou A, Walker RG, Russ GR, et al. Diltiazem in renal allograft recipients receiving cyclosporine. Transplantation 1993; 55:300-304.
10. Ladefoged SD, Pedersen E, Hammer M, et al. Influence of diltiazem on renal function and rejection in renal allograft recipients receiving triple-drug immunosuppression: a randomized, double-blind, placebo-controlled study. Nephrol Dial Transplant 1994; 9:543-547.
11. Calne R, Friend P, Moffatt S, et al. Prope tolerance, perioperative Campath 1H, and low-dose cyclosporine monotherapy in renal allograft recipients. Lancet 1998; 351:1701-1702.
12. Watson CJ, Bradley JA, Friend PJ, et al. Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation: efficacy and safety at five years. Am J Transplant 2005; 5:1347-1353.
13. Tan HP, Kaczorowski DJ, Basu A, Unruh M, et al. Living donor renal transplantation using alemtuzumab induction and tacrolimus monotherapy. Am J Transplant 2006; 6:2409-2417. This was a single-center study of alemtuzumab induction combined with reduced doses of TAC in 207 living donor renal transplantations with a 6.8% ratio of acute rejection episodes versus 17% for a historic cohort of 47 subjections receiving full-dose TAC, MMF and prednisone.
14. Qazi YA, Singh N, Gundroo A, Khalil F, et al. One year results of alemtuzumab (Campath-1H) induction, calcineurin minimization protocol in renal transplant recipients monitored by surveillance biopsies [abstract]. Am J Transplant 2007; 7 (Suppl 2):444-445.
15. Zeevi A, Bentlejewski C, Rai V, et al. Correlation of immune function monitoring with tapering of tacrolimus in long-term renal allograft recipients [abstract]. Am J Transplant 2007; 7 (Suppl 2):445.
16. Kahan BD. Individualization of cyclosporine therapy using pharmacokinetic and pharmacodynamic parameters. Transplantation 1985; 40:457-476.
17. Kahan BD, Grevel J. Overview: Optimization of cyclosporine therapy in renal transplantation by a pharmacokinetic strategy. Transplantation 1988; 46:631-644.
18. Lindholm A, Kahan BD. Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation. Clin Pharmacol Ther 1993; 54:205-218.
19. Amante AJ, Kahan BD. Abbreviated area-under-the-curve strategy for monitoring cyclosporine microemulsion therapy in immediate posttransplant period. Clin Chem 1996; 42:1294-1296.
20. Canadian Neoral Renal Transplantation Study Group. Absorption profiling of cyclosporine microemulsion (Neoral) during the first 2 weeks after renal transplantation. Transplantation 2001; 72:1024-1032.
21. 0-tacrolimus on renal function and cardiovascular risk factors in kidney transplant recipients. Transplantation 2006; 82:924-930.
22. Levy G, Burra P, Cavallari A, et al. Improved clinical outcomes for liver transplant recipients using cyclosporine monitoring based on 2-hr postdose levels (C2). Transplantation 2002; 73:953.
23. Pfeffer P, Stefoni S, Carreno CA, et al. Monitoring of 2-h neoral absorption in renal transplantation (MO2ART): Interim analysis shows low incidence of acute rejection in the early postgraft period. Abstract 1037. Am J Transplant 2002; 2 (Suppl 3):399.
24. Thervet E, Pfeffer P, Scolari MP, et al. Clinical outcomes during the first three months posttransplant in renal allograft recipients managed by C2 monitoring of cyclosporine microemulsion. Transplantation 2003; 76:903-908.
25. 2 monitoring of cyclosporine A microemulsion: Results of a 12-month, randomized, multicenter study. Transplantation 2005; 79:577-583.
26. 0 monitoring in de novo liver transplantation. Transplantation 2004; 77:1632-1638.
27. Levy G, Grazi GL, Sanjuan F, et al. 12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus. Liver Transplantation 2006; 12:1464-1472.
28. Cosio FG, Amer H, Grande JP, et al. Comparison of low versus high tacrolimus levels in kidney transplantation: assessment of efficacy by protocol biopsies. Transplantation 2007; 83:411-416.
29. Vincenti F, Ramos E, Brattstrom C, et al. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation. Transplantation 2001; 71:1292-1287.
30. Halloran P, Mathew T, Tomlanovich S, et al. Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups. Transplantation 1997; 63:39-47.
31. Gonzalez Molina M, Seron D, Garcia del Moral R, et al. Mycophenolate mofetil reduces deterioration of renal function in patients with chronic allograft nephropathy. A follow-up study by the Spanish Cooperative Study Group of Chronic Allograft Nephropathy. Transplantation 2004; 77:215-220.
32. Merville P, Berge F, Deminiere C, et al. Lower incidence of chronic allograft nephropathy at 1 year posttransplantation in patients treated with mycophenolate mofetil. Am J Transplant 2004; 4:1769-1775.
33. Ekberg H, Grinyo J, Nashan B, et al. Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: The CAESAR Study. Am J Transplant 2007; 7:560-570. This multicenter randomized trial in 536 renal transplant recipients of low-dose CsA followed by withdrawal versus continuous low-dose CsA versus standard-dose CsA in combination with daclizumab, MMF and steroids showed the danger of withdrawal.
34. Knechtle SJ, Pirsch JD, Fechner J Jr, et al. Campath-1H induction plus rapamycin monotherapy for renal transplantation: Results of a pilot study. Am J Transplant 2003; 3:722-730.
35. Flechner SM, Friend PJ, Brockmann J, et al. Alemtuzumab induction and sirolimus plus mycophenolate mofetil maintenance for CNI and steroid-free kidney transplant immunosuppression. Am J Transplant 2005; 5:3009-3014.
36. Flechner SM, Kurian SM, Solez K, et al. De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years. Am J Transplant 2004; 4:1776-1785.
37. Flechner SM, Glyda M, Steinberg S, Harler MB, the ORION Trial Investigators. A randomized, open-label study to compare the safety and efficacy of two different sirolimus (SRL) regimens with a tacrolimus (Tac) and mycophenolate mofetil regimen (MMF) in de novo renal allograft recipients: Acute rejection and graft survival results from the ORION study. Abstract 52. Am J Transplant 2007; 7 (Suppl 2):160.
38. Flechner SM, Glyda M, Steinberg S, Harler MB, for the ORION Trial Investigators. A randomized, open-label study to compare the safety and efficacy of two different sirolimus (SRL) regimens with a tacrolimus (Tac) and mycophenolate mofetil regimen (MMF) in de novo renal allograft recipients: Renal function results from the ORION study [abstract]. Am J Transplant 2007; 7 (Suppl 2):440.
39. Larson TS, Dean PG, Stegall MD, et al. Complete avoidance of calcineurin inhibitors in renal transplantation: A randomized trial comparing sirolimus and tacrolimus. Am J Transplant 2006; 6:514-522.
40. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Symphony: comparing standard immunosuppression to low-dose cyclosporine, tacrolimus or sirolimus in combination with MMF, daclizumab and corticosteroids in renal transplantation [abstract]. Am J Transplant 2006; 6 (Suppl 2):83.
41. Ekberg H, Vincenti F, Tedesco da Silva H, et al. Low-dose sirolimus in the first 8 weeks following renal transplantation accompanied by daclizumab induction, MMF and steroids: The experience of the Symphony study. Abstract 691. Am J Transplant 2006; 6 (Suppl 2):300.
42. Grinyo J, Ekberg H, Oppenheimer F, et al. Pharmacokinetics of total and free mycophenolic acid (MPA) when mycophenolate mofetil (MMF) is administered with low-dose tacrolimus, low-dose sirolimus or standard-dose cyclosporine in renal transplantation. Results of the Symphony PK substudy [abstract]. Am J Transplant 2006; 6 (Suppl 2):345.
43. Kahan BD, Kramer WG. Median effect analysis of efficacy versus adverse effects of immunosuppressants. Clin Pharm Ther 2001; 70:74-81.
44. Podder H, Stepkowski SM, Napoli K, et al. Pharmacokinetic interactions augment toxicities of sirolimus/cyclosporine combinations. J Am Soc Nephrol 2001; 12:1059-1071.
45. Kahan BD, Julian BA, Pescovitz MD, et al. Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in Caucasian recipients of mismatched primary renal allografts: a phase II trial. Transplantation 1999; 68:1526-1532.
46. Nashan B, Curtis J, Ponticelli C, et al. Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: a three-year phase II, randomized, multicenter, open-label study. Transplantation 2004; 78:1332-1340.
47. Lehmkuhl H, Ross H, Eisen H, et al. Everolimus (Certican) in heart transplantation: Optimizing renal function through minimizing cyclosporine exposure. Transplant Proc 2005; 37:4145-4149.
48. Gaber AO, Kahan BD, Van Buren CT, et al. An open-label, randomized study of high-risk renal allograft patients receiving sirolimus and tacrolimus compared with sirolimus and cyclosporine: 12-month safety results [abstract]. Am J Transplant 2006; 6 (Suppl 2):240.
49. Cole E, Maham N, Cardella C, et al. Clinical benefits of neoral C2 monitoring in long-term management of renal transplant recipients. Transplantation 2003; 75:2086-2090.
50. Abramowicz D, Del Carmen Rial M, Vitko S, et al. Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen: results of a five-year, prospective, randomized study. J Am Soc Nephrol 2005; 16:2234-2240.
51. Frimat L, Cassuto-Viguier E, Charpentier B, Noel C, et al. Impact of cyclosporine reduction with MMF: a randomized trial in chronic allograft dysfunction. The "reference" study. Am J Transplant 2006; 6:2725-2734. This randomized trial showed the benefit on renal function of MMF introduction accompanied by a 50% decrease in CsA levels.
52. Langers P, Cremers SC, den Hartigh J, et al. Switching monitoring of emulsified cyclosporine from trough level to 2-hour level in stable liver transplant patients. Liver Transpl 2004; 10 (2):190-192.
53. 2 levels in long-term liver transplant patients. Clin Transplant 2005; 19:537-542.
54. Cantarovich M, Elstein E, De Varennes B, Barkun JS. Clinical benefit of neoral dose monitoring with cyclosporine 2-hr postdose levels compared with trough levels in stable heart transplant patients. Transplantation 1999; 68:1839-1842.
55. Dudley C, Pohanka E, Riad H, et al. Mycophenolate mofetil substitution for cyclosporine in renal transplant recipients with chronic progressive allograft dysfunction: the "creeping creatinine" study. Transplantation 2005; 79:466-475.
56. Filler G, Gellermann J, Zimmering M, Mai I. Effect of adding mycophenolate mofetil in paediatric renal transplant recipients with chronical cyclosporine nephrotoxicity. Transpl Int 2000; 13:201-206.
57. David-Neto E, Araujo LM, Lemos FC, et al. Introduction of mycophenolate mofetil and cyclosporine reduction in children with chronic transplant nephroxicity. Pediatr Transplant 2001; 5:302-309.
58. Benz K, Plank C, Griebel M, et al. Mycophenolate mofetil introduction stabilizes and subsequent cyclosporine A reduction slightly improves kidney function in pediatric renal transplant patients: a retrospective analysis. Pediatr Transplant 2006; 10:331-336.
59. Mourad G, Vela C, Ribstein J, Mimran A. Long-term improvement in renal function after cyclosporine dose reduction in renal transplant recipients with histologically proven chronic cyclosporine nephrotoxicity. Transplantation 1998; 65:661-667.
60. Suwelack B, Gerhardt U, Hohage H. Withdrawal of cyclosporine or tacrolimus after addition of mycophenolate mofetil in patients with chronic allograft nephropathy. Am J Transplant 2004; 4:655-662.
61. Morath C, Zeier M. Review of the antiproliferative properties of mycophenolate mofetil in nonimmune cells. Int J Clin Pharmacol Ther 2003; 41:465-469.
62. Henne T, Latta K, Strehlau J, et al. Mycophenolate mofetil-induced reversal of glomerular filtration loss in children with chronic allograft nephropathy. Transplantation 2003; 76:1326-1330.
63. Urbanowicz AL, Perkowska A, Cieciura T, Baczkowska T, et al. Long term outcome of mycophenolate mofetil addition to cyclosporine in kidney transplant recipients with chronic allograft nephropathy [abstract]. Am J Transplant 2007; 7 (Suppl 2):446.
64. Marx SO, Jayaraman T, Go LO, Marks AR. Rapamycin inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ Res 1995; 76:412-417.
65. Gregory CR, Huang X, Pratt RE, et al. Treatment with rapamycin and MMF reduces arterial intimal thickening produced by mechanical injury and allows endothelial replacement. Transplantation 1995; 59:655-661.
66. Obata T, Kashiwagi A, Maegawa H, et al. Insulin signaling and its regulation of system A amino acid uptake in cultured rat vascular smooth muscle cells. Circ Res 1996; 79:1167-1176.
67. Mohasci PJ, Tuller D, Hullinger B, et al. Different inhibitory effects of immunosuppressive drugs on human and rat aortic smooth muscle and endothelial cell proliferation stimulated by platelet derived growth factor or endothelial cell growth factor. J Heart Lung Transplant 1997; 16:484-492.
68. Ikonen TS, Gummert JP, Hayase M, et al. Sirolimus (rapamycin) halts and reverses progression of allograft vascular disease in nonhuman primates. Transplantation 2000; 70:969-975.
69. Khanna AK. Mechanism of the combination immunosuppressive effects of rapamycin with either cyclosporine or tacrolimus. Transplantation 2000; 70:690-694.
70. Saunders RN, Bicknell GR, Nicholson L. The impact of cyclosporine dose reduction with or without the addition of rapamycin on functional, molecular, and histological markers of chronic allograft nephropathy. Transplantation 2003; 75:772-780.
71. Johnson RWG, Kreis H, Oberbauer R, et al. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 2001; 72:777-786.
72. Russ G, Segoloni G, Oberbauer R, et al., for the Rapamune Maintenance Regimen Study Group. Superior outcomes in renal transplantation after early cyclosporine withdrawal and sirolimus maintenance therapy, regardless of baseline renal function. Transplantation 2005; 80:1204-1211.
73. Oberbauer R, Segoloni G, Campistol JM, et al. Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation. Transplant International 2005; 18:22-28.
74. Legendre C, Brault Y, Morales JM, et al. Factors influencing glomerular filtration rate in renal transplantation after cyclosporine withdrawal using sirolimus-based therapy: a multivariate analysis of results at five years. Clin Transplant 2007; 21:330-336.
75. Gonwa TA, Hricik DE, Brinker K, et al. Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination. Transplantation 2002; 74:1560-1567.
76. Oberbauer R, Schena FP, Wali R, et al. Conversion from calcineurin inhibitors to sirolimus compared with continued use of calcineurin inhibitors in renal allograft recipients: 24-month safety and efficacy results from the CONVERT trial [abstract]. J Am Soc Nephrol 2006; 17:69A.
77. Mulay AV, Cockfield S, Stryker R, et al. Conversion from calcineurin inhibitors to sirolimus for chronic renal allograft dysfunction: a systematic review of the evidence. Transplantation 2006; 82:1153-1162. A meta-analysis of data available from randomized and nonrandomized studies presents a balanced view of CNI to SRL conversion.
78. Patel A, Weir M, Wali R, Pearson T, et al. Spare-the-nephron (STN) trial: Updated analysis of renal function after one year of mycophenolate mofetil/sirolimus maintenance therapy and calcineurin inhibitor withdrawal in renal transplant recipients [abstract]. Am J Transplant 2007; 7 (Suppl 2):439-440.
79. Chhabra D, Parker M, Leventhal J, Friedewald J, et al. Conversion of calcineurin-inhibitors (FK506 to sirolimus) at 1 year post transplant in a prednisone-free immunosuppression regimen: Impact on incidence of acute cellular rejection and renal allograft function [abstract]. Am J Transplant 2007; 7 (Suppl 2):440.
80. Wali RK, Mohanlal V, Ramos E, Blahut S, et al. Early withdrawal of calcineurin inhibitors and rescue immunosuppression with sirolimus-based therapy in renal transplant recipients with moderate to severe renal dysfunction. Am J Transplant 2007; 7:1572-1583.
81. Egidi MF, Cowan PA, Naseer A, et al. Conversion to sirolimus in solid organ transplantation: a single-centre experience. Transplant Proc 2003; 35 (Suppl 3A):131S-137S.
82. Groetzner J, Meiser B, Landwehr P, et al. Mycophenolate mofetil and sirolimus as calcineurin inhibitor-free immunosuppression for late cardiac-transplant recipients with chronic renal failure. Transplantation 2004; 77:568-574.
83. Diekmann F, Budde K, Oppenheimer F, et al. Predictors of success in conversion from CNI to sirolimus in chronic allograft dysfunction. Am J Transplant 2004; 4:1869-1875.
84. Watson CJ, Firth J, Williams PF, et al. A randomized controlled trial of late conversion from CNI-based to sirolimus-based immunosuppression following renal transplantation. Am J Transplant 2005; 5:2496-2503.
85. Baboolal K. Six month interim analysis of a phase III prospective, randomized study to compare conversion from CNIs to rapamycin in established renal allograft recipients on maintenance therapy with mild to moderate renal insufficiency [abstract]. Am J Trans 2004; 4 (Suppl 8):220.
86. Smak GPJH, de Sevaux RG, Ligtenberg G, et al. Withdrawal of cyclosporine or prednisone six months after kidney transplantation in patients on triple drug therapy: a randomized, prospective, multicenter study. J Am Soc Nephrol 2002; 13:1365-1373.
87. Schnuelle P, van der Heide JH, Tegzess A, et al. Open randomized trial comparing early withdrawal of either cyclosporine or mycophenolate mofetil in stable renal transplant recipients initially treated with a triple drug regimen. J Am Soc Nephrol 2002; 13:536-543.
88. Hollander AAMJ, van Saase JLCM, Kootte AMM, et al. Beneficial effects of conversion from cyclosporine to azathioprine after kidney transplantation. Lancet 1995; 345:610-614.
89. Hilbrands LB, Hoitsma AJ, Koene RAP. Randomized, prospective trial of cyclosporine monotherapy versus azathioprine prednisone from three months after renal transplantation. Transplantation 1996; 61:1038-1046.
90. MacPhee IAM, Bradley JA, Briggs JD, et al. Long-term outcome of a prospective randomized trial of conversion from cyclosporine to azathioprine treatment one year after renal transplantation. Transplantation 1998; 66:1186-1192.
91. Sennesael JJ, Bosmans JL, Bogers JP, et al. Conversion from cyclosporine to sirolimus in stable renal transplant recipients. Transplantation 2005; 80:1578-1585.
92. Rahamimov R, Lustig S, Yussim A, Winkler J, et al. What should the urine protein excretion threshold for conversion from calcineurin inhibitor to sirolimus based protocol after kidney transplantation? Abstract 1166. Am J Transplant 2007; 7 (Suppl 2):446.
93. Tuzuner A, Mead H, Sar A, Monroy M, et al. Clinical predictors for proteinuria development in patients converted to sirolimus base therapy [abstract]. Am J Transplant 2007; 7 (Suppl 2):447.
94. Butani L. Investigation of pediatric renal transplant recipients with heavy proteinuria after sirolimus rescue. Transplantation 2004; 78:1362-1366.
95. Ruiz JC, Campistol JM, Sanchez-Fructuoso A, Mota A, et al. Early sirolimus use with CsA elimination does not induce progressive proteinuria. Abstract 1150. Am J Transplant 2007; 7 (Suppl 2):442-443.
96. Stigant CE, Cohen J, Vivera M, et al. ACE inhibitors and angiotensin II antagonists in renal transplantation: an analysis of safety and efficacy. Am J Kidney Dis 2000; 35:58-63.
97. Guasch A, Barakat I, Near M, Selvaraj S. Conversion to sirolimus from a calcineurin inhibitor based protocol does not worsen proteinuria or glomerular permeability to macromolecules in patients with chronic allograft nephropathy. Abstract 1145. Am J Transplant 2007; 7 (Suppl 2):441.
98. Bonegio RG, Fuhro R, Wang Z, et al. Rapamycin ameliorates proteinuria-associated tubulointerstitial inflammation and fibrosis in experimental membranous nephropathy. J Am Soc Nephrol 2005; 16:2063-2072.
99. Peddi VR, Jensik S, Pescovitz M, et al. An open-label, pilot study evaluating the safety and efficacy of converting from calcineurin inhibitors to sirolimus in established renal allograft recipients with moderate renal insufficiency. Clin Transplant 2005; 19:130-136.
100. Goggins MO, Patel A, Khalil C, Patel H, et al. Single-center experience on rapamycin substitution in renal transplant recipients with chronic allograft nephropathy: 12 month follow-up [abstract]. Am J Transplant 2007; 7 (Suppl 2):441.
101. Mota A. Sirolimus: a new option in transplantation. Expert Opin Pharmacother 2005; 6:479-487.
102. Vincenti F, Larsen C, Durrbach A, et al. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005; 353:770-781.
103. Wagner J, Evenou J-P, Zenke G, et al. The first-in-class oral protein kinase C (PKC) inhibitor NVP-AEB071 (AEB) prolongs renal allograft survival in nonhuman primates (NHP) and suppresses lymphocyte proliferation at safe exposures in human proof-of-concept studies [abstract]. Am J Transplant 2006; 6 (Suppl 2):86.
104. Kahan BD. Individuality: the barrier to optimal immunosuppression. Nature Rev Immunol 2003; 3:831-838.
105. Weimar W, Gaston R, Brennan D, et al. Phase I evaluation of the safety of JAK3 inhibitor, CP-690,550 in stable kidney transplant recipients. Abstract 58. Am J Transplant 2006; 6 (Suppl 2):86.
106. Quarto Di Palo F, Castagnone D, Rivolta R, et al. Cyclosporine renal cortical vasoconstriction measured by colour doppler imaging in kidney transplantation. Transplant Int 1992; 5:21-22.
107. Knight RJ, Kerman RH, Schoenberg L, et al. The selective use of basiliximab versus thymoglobulin in combination with sirolimus for cadaveric renal transplant recipients at low versus high risk for delayed graft function. Transplantation 2004; 78:904-910.
108. Knight RJ, Kahan BD. The place of sirolimus in kidney transplantation: Can we reduce calcineurin inhibitor renal toxicity? Kidney International 2006; 70:994-999.
109. Rice JE, Shipp AT, Carlin JB, et al. Late reduction in cyclosporine dosage does not improve renal function in pediatric heart transplant recipients. J Heart Lung Transplant 2002; 21:1109-1112.
110. Citterio F, Scata MC, Violi P, et al. Rapid conversion to sirolimus for chronic progressive deterioration of the renal function in kidney allograft recipients. Transplant Proc 2003; 35:1292-1294.
111. Dominguez J, Mahalati K, Kiberd B, et al. Conversion to rapamycin immunosuppression in renal transplant recipients: report of an initial experience. Transplantation 2000; 70:1244-1247.
112. Bodziak KA, Hricik DE. Conversion from calcineurin inhibitors to mTOR inhibitors. Curr Opin Organ Transplant 2007; 12:351-356.